AI assistant
Sending…
RELMADA THERAPEUTICS, INC. — Director's Dealing 2025
Jul 1, 2025
34465_dirs_2025-06-30_f45968da-9893-415a-bd0f-54457b2b8275.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2025-06-26
Reporting Person: Shenouda Maged (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-26 | Stock Option (right to buy) | $0.67 | A | 600000 | Acquired | 2035-06-26 | Common Stock (600000) | Direct |
Footnotes
F1: The options vest in 16 equal quarterly installments commencing on September 26, 2025.
More from RELMADA THERAPEUTICS, INC.
Declaration of Voting Results & Voting Rights Announcements
2026
May 28
Share Issue/Capital Change
2026
May 13
Regulatory Filings
2026
May 12
Capital/Financing Update
2026
Apr 9
Regulatory Filings
2026
Mar 20
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 12
Capital/Financing Update
2026
Jan 30
Director's Dealing
2025
Dec 16